261 related articles for article (PubMed ID: 24638012)
21. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study.
Zucca E; Conconi A; Laszlo D; López-Guillermo A; Bouabdallah R; Coiffier B; Sebban C; Jardin F; Vitolo U; Morschhauser F; Pileri SA; Copie-Bergman C; Campo E; Jack A; Floriani I; Johnson P; Martelli M; Cavalli F; Martinelli G; Thieblemont C
J Clin Oncol; 2013 Feb; 31(5):565-72. PubMed ID: 23295789
[TBL] [Abstract][Full Text] [Related]
22. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
Davids MS; Brander DM; Kim HT; Tyekucheva S; Bsat J; Savell A; Hellman JM; Bazemore J; Francoeur K; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng S; Crombie J; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Fisher DC; Brown JR;
Lancet Haematol; 2019 Aug; 6(8):e419-e428. PubMed ID: 31208944
[TBL] [Abstract][Full Text] [Related]
23. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience.
Herishanu Y; Goldschmidt N; Bairey O; Ruchlemer R; Fineman R; Rahimi-Levene N; Shvidel L; Tadmor T; Ariel A; Braester A; Shapiro M; Joffe E; Polliack A;
Haematologica; 2015 May; 100(5):662-9. PubMed ID: 25661442
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of the obinutuzumab-chlorambucil combination in the frontline treatment of elderly CLL patients with comorbidities - Polish Adult Leukemia Group (PALG) real-life analysis.
Długosz-Danecka M; Jurczak W; Łątka-Cabała E; Morawska M; Gawroński K; Wiśniewska A; Dudziński M; Wąsik-Szczepanek E; Chmielowska E; Łabędź A; Wdowiak K; Hus I
Pol Arch Intern Med; 2018 Aug; 128(7-8):421-426. PubMed ID: 30057377
[TBL] [Abstract][Full Text] [Related]
26. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
[TBL] [Abstract][Full Text] [Related]
27. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.
Robak T; Dmoszynska A; Solal-Céligny P; Warzocha K; Loscertales J; Catalano J; Afanasiev BV; Larratt L; Geisler CH; Montillo M; Zyuzgin I; Ganly PS; Dartigeas C; Rosta A; Maurer J; Mendila M; Saville MW; Valente N; Wenger MK; Moiseev SI
J Clin Oncol; 2010 Apr; 28(10):1756-65. PubMed ID: 20194844
[TBL] [Abstract][Full Text] [Related]
28. A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia.
Reynolds C; Di Bella N; Lyons RM; Hyman W; Richards DA; Robbins GJ; Vellek M; Boehm KA; Zhan F; Asmar L
Invest New Drugs; 2012 Jun; 30(3):1232-40. PubMed ID: 21922186
[TBL] [Abstract][Full Text] [Related]
29. Phase II study of lenalidomide and rituximab as salvage therapy for patients with relapsed or refractory chronic lymphocytic leukemia.
Badoux XC; Keating MJ; Wen S; Wierda WG; O'Brien SM; Faderl S; Sargent R; Burger JA; Ferrajoli A
J Clin Oncol; 2013 Feb; 31(5):584-91. PubMed ID: 23270003
[TBL] [Abstract][Full Text] [Related]
30. Chlorambucil plus theophylline vs chlorambucil alone as a front line therapy for B-cell chronic lymphatic leukemia.
Mabed M; Aref S; Fouda M; El-Sharawy S
Leuk Lymphoma; 2004 Oct; 45(10):2029-35. PubMed ID: 15370247
[TBL] [Abstract][Full Text] [Related]
31. Ofatumumab combined with chlorambucil for previously untreated chronic lymphocytic leukemia: a phase I/II, open-label study in Japan.
Hatake K; Ogura M; Takada K; Taniwaki M; Zhang F; Fujita T; Ando K
Int J Hematol; 2017 Aug; 106(2):240-247. PubMed ID: 28421390
[TBL] [Abstract][Full Text] [Related]
32. Combination of rituximab with chlorambucil as first line treatment in patients with mantle cell lymphoma: a highly effective regimen.
Sachanas S; Pangalis GA; Vassilakopoulos TP; Korkolopoulou P; Kontopidou FN; Athanasoulia M; Yiakoumis X; Kalpadakis C; Georgiou G; Masouridis S; Moschogiannis M; Tsirkinidis P; Pappis V; Kokoris SI; Siakantaris MP; Panayiotidis P; Angelopoulou MK
Leuk Lymphoma; 2011 Mar; 52(3):387-93. PubMed ID: 21133713
[TBL] [Abstract][Full Text] [Related]
33. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group.
Fischer K; Cramer P; Busch R; Stilgenbauer S; Bahlo J; Schweighofer CD; Böttcher S; Staib P; Kiehl M; Eckart MJ; Kranz G; Goede V; Elter T; Bühler A; Winkler D; Kneba M; Döhner H; Eichhorst BF; Hallek M; Wendtner CM
J Clin Oncol; 2011 Sep; 29(26):3559-66. PubMed ID: 21844497
[TBL] [Abstract][Full Text] [Related]
34. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.
Fischer K; Al-Sawaf O; Bahlo J; Fink AM; Tandon M; Dixon M; Robrecht S; Warburton S; Humphrey K; Samoylova O; Liberati AM; Pinilla-Ibarz J; Opat S; Sivcheva L; Le Dû K; Fogliatto LM; Niemann CU; Weinkove R; Robinson S; Kipps TJ; Boettcher S; Tausch E; Humerickhouse R; Eichhorst B; Wendtner CM; Langerak AW; Kreuzer KA; Ritgen M; Goede V; Stilgenbauer S; Mobasher M; Hallek M
N Engl J Med; 2019 Jun; 380(23):2225-2236. PubMed ID: 31166681
[TBL] [Abstract][Full Text] [Related]
35. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.
Hallek M; Fischer K; Fingerle-Rowson G; Fink AM; Busch R; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Bergmann M; Catalano J; Zinzani PL; Caligaris-Cappio F; Seymour JF; Berrebi A; Jäger U; Cazin B; Trneny M; Westermann A; Wendtner CM; Eichhorst BF; Staib P; Bühler A; Winkler D; Zenz T; Böttcher S; Ritgen M; Mendila M; Kneba M; Döhner H; Stilgenbauer S; ;
Lancet; 2010 Oct; 376(9747):1164-74. PubMed ID: 20888994
[TBL] [Abstract][Full Text] [Related]
36. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium.
James DF; Werner L; Brown JR; Wierda WG; Barrientos JC; Castro JE; Greaves A; Johnson AJ; Rassenti LZ; Rai KR; Neuberg D; Kipps TJ
J Clin Oncol; 2014 Jul; 32(19):2067-73. PubMed ID: 24868031
[TBL] [Abstract][Full Text] [Related]
37. Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy.
Zucca E; Conconi A; Martinelli G; Bouabdallah R; Tucci A; Vitolo U; Martelli M; Pettengell R; Salles G; Sebban C; Guillermo AL; Pinotti G; Devizzi L; Morschhauser F; Tilly H; Torri V; Hohaus S; Ferreri AJM; Zachée P; Bosly A; Haioun C; Stelitano C; Bellei M; Ponzoni M; Moreau A; Jack A; Campo E; Mazzucchelli L; Cavalli F; Johnson P; Thieblemont C
J Clin Oncol; 2017 Jun; 35(17):1905-1912. PubMed ID: 28355112
[TBL] [Abstract][Full Text] [Related]
38. Consolidation therapy with subcutaneous alemtuzumab after fludarabine and rituximab induction therapy for previously untreated chronic lymphocytic leukemia: final analysis of CALGB 10101.
Lin TS; Donohue KA; Byrd JC; Lucas MS; Hoke EE; Bengtson EM; Rai KR; Atkins JN; Link BK; Larson RA
J Clin Oncol; 2010 Oct; 28(29):4500-6. PubMed ID: 20697069
[TBL] [Abstract][Full Text] [Related]
39. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study.
Burger JA; Keating MJ; Wierda WG; Hartmann E; Hoellenriegel J; Rosin NY; de Weerdt I; Jeyakumar G; Ferrajoli A; Cardenas-Turanzas M; Lerner S; Jorgensen JL; Nogueras-González GM; Zacharian G; Huang X; Kantarjian H; Garg N; Rosenwald A; O'Brien S
Lancet Oncol; 2014 Sep; 15(10):1090-9. PubMed ID: 25150798
[TBL] [Abstract][Full Text] [Related]
40. Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL.
Hillmen P; Janssens A; Babu KG; Kloczko J; Grosicki S; Manson S; McKeown A; Gupta I; Chang CN; Offner F
Acta Oncol; 2016; 55(9-10):1115-1120. PubMed ID: 27494089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
